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Angiogenesis is a tightly regulated process that normally occurs
during embryonic development and is suppressed in adult life. We
have previously demonstrated that somatostatin (SRIF) analogues
will inhibit angiogenesis in the chicken chorioallantoic membrane
(CAM) and in the rabbit corneal micropocket models (Woltering 
et al, 1991; Patel et al, 1994; Barrie et al, 1993; Conway et al,
1996). These observations have been confirmed by Danesi et al,
who demonstrated that somatostatin analogues will inhibit angio-
genesis in the CAM model and will inhibit the proliferation of
human umbilical vein endothelial cells (HUVECs) in culture
(Danesi et al, 1997). In our previous studies, we demonstrated that
SRIF-induced inhibition of angiogenesis in the CAM is G-protein-
adenylate cylase-, and calcium-dependent (Patel et al, 1994). We
have also shown that the ability of a somatostatin analogue to
inhibit angiogenesis is proportional to its sst 2-binding affinity and
its ability to inhibit growth hormone release, a sst 2-dependent
process (Woltering et al, 1997). These observations imply that
endothelial cells growing from human blood vessels express sst 2.
External scintigraphic scanning with the sst 2-preferring analogue,
111In-pentetreotide, has demonstrated binding to cells in malignant
tissue and to cells in non-malignant tissue in which angiogenesis is
occurring but not to normal blood vessels. Similarly, van Hagen 
et al demonstrated that 111In-pentetreotide localizes to active
rheumatoid joints but not to osteoarthritic joints (van Hagen et al,
1994). These authors postulated that the radiolabelled somatostatin
analogue binds to the vascular pannus in active rheumatoid joints but
does not bind to cells in non-vascularized, normal or osteoarthritic
joints (van Hagen et al, 1994). Reubi et al, using autoradio-
graphic techniques have demonstrated that proliferating human
peritumoral vessels bind 125I-tyr3-octreotide, a sst 2-preferring
radioligand, while distant quiescent vessels do not (Reubi 
et al, 1994, 1996; Denzler and Reubi, 1999). 
Based on these observations, we hypothesized that non-
proliferating human vascular endothelial cells do not express sst 2
but these receptors are expressed when endothelial cells prolif-
erate. To test this hypothesis, normal placental veins were
harvested from 6 human placentas obtained immediately fol-
lowing delivery. RNA was harvested from quiescent (native)
placental vessels and from vessel fragments which had been
cultured in vitro. In this culture system, we have investigated
changes in gene expression as vascular endothelial cells begin to
sprout, migrate, and proliferate (Watson et al, 1996). Previous
work in our laboratories using this culture system revealed that the
gene for a vascular endothelial growth factor (VEGF) receptor,
kdr, is expressed in angiogenic vein disks but not in placental
vessels in which endothelial growth is not occurring. 
METHODS 
In vitro culture of human placental veins 
Fresh human placentas were obtained from 6 anonymous donors
following guidelines established by the LSU Institutional Review
Board, Protocol #2828. Placental veins were trimmed of
surrounding tissue, opened longitudinally and 2 mm diameter
disks prepared using a sterile skin biopsy punch. Residual
placental vein tissue was placed in Ultraspec® RNA isolation
solution (Biotex, Inc, Houston, TX) for subsequent RNA extrac-
tion. Vein disks (N = 100/assay) were incorporated into 0.3%
fibrin gels in complete tissue culture medium containing 20% fetal
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bovine serum (FBS), e-amino caproic acid, antibiotics and anti-
fungals. Fibrin gels were overlaid with tissue culture medium
consisting of minimal essential medium (MEM, Gibco, Grand
Island, NY), supplemented with 10% FBS, penicillin, strepto-
mycin and Fungizone according to methods outlined by Watson et
al and Brown et al (Brown et al, 1996; Watson et al, 1996). Culture
plates were incubated in a 5% CO2/95% air atmosphere at 37°C for
15 days and observed daily with an inverted microscope. At 15
days, cultures exhibiting endothelial cell growth and those not
exhibiting an angiogenic response were collected for RNA isolation.
Separate experiments with cultured, nonangiogenic vein disks were
performed to determine if their failure to proliferate was due to poor
cell viability. The MTT cell viability assay (Promega Corporation,
Madison, WI) confirmed that these disks contained viable cells even
though they did not exhibit an angiogenic response. 
Reverse transcription-polymerase chain reaction 
(RT-PCR) analysis of gene expression 
Venous tissue collected at the time of preparation of the disks,
cultured disks that did not develop endothelial sprouts and disks
which developed sprouts were collected in separate RNase-free
tubes and homogenized in an RNA isolation solution (RNAzol,
Biotex, Houston, TX). RNA from each sample was quantitated by
A260/A280 spectrophotometric analysis. 500 ng of RNA was reverse
transcribed in the presence of random hexamer primers using a
reverse transcription system (Perkin-Elmer Applied Biosystems,
Carson City, CA). The expression of the sst 2 gene and the consti-
tutively expressed gene for glyceraldehyde-6-phosphodehydroge-
nase (GAPDH) was determined by amplifying the cDNAs from
non-proliferating and from proliferating placental endothelial
cells. Following 35 amplification cycles, the gene products were
analysed on 2% agarose gels stained with ethidium bromide.
Visualization of the amplified gene products was performed with
an Eagle-EyeII® gel documentation system (Stratagene, Inc, La
Jolla, CA) (Figure 1). Nucleotide sequences of the primers and
probes used are given in Table 1. 
Southern hybridization 
Southern hybridization was used to confirm the identity of the
amplified gene products. DNA probes, complementary to an
internal sequence of the amplified sst 2 and GAPDH amplicons
(Table 1), were labelled with biotin (Ready-To-Go beads,
Pharmacia Biotech, Piscataway, NJ). 10 mg of labelled probe in
Express Hyb® hybridization solution was incubated with nitrocel-
lulose membranes (Tropilon Plus, Tropix Inc, Bedford, MA) to
which were bound the amplified products. The hybridized biotin-
labelled probes were detected using the Southern-Light® detec-
tion system (Tropix). Autoradiography was performed on X-ray
film (X-OMAT AR, Kodak Corp., Rochester, NY). 
Localization of radiolabelled somatostatin analogues in
angiogenic vessels in vivo 
Nude mice (Harlan Sprague Dawley, Indianapolis, IN) were
injected in the hindquarter with 1 ´ 106 SKNSH human neuroblas-
toma tumour cells, in accordance with LSUHSC Institutional
Animal Care and Use Committee approved Protocol #1806.
SKNSH cells do not express sst 2 as measured by both RT-PCR
and in vitro binding assays (O’Dorisio et al, 1994). Injection sites
were observed for 2–3 months until tumours grew to 2 cm in 
diameter. Mice were injected in the tail vein with 3 mCi of
125I-WOC4a[DTyr-Tyr-Tyr-DTyr-Cys-Phe-DTrp-Lys-Thr-Cys-
Thr], an sst 2-preferring somatostatin analogue (Woltering et al,
1998). We have previously shown that this radioiodinated
analogue has a high binding affinity for sst 2 (Kd~1nM) and will
induce receptor-specific cytotoxicity in human (IMR32) neurob-
lastoma cells (Meyers et al, 1998). Background counts were
allowed to clear for 5 days, and the mice were then scanned and
radiographed. Because of the low energy emissions of 125I, mice
were scanned on both their ventral and dorsal surfaces. 
Preparation of sst 2 antiserum 
An oligonucleotide corresponding to the N terminal 45 amino
acids of sst 2 was cloned into pET-32a(+) vector (Norvagen,
Madison, WI) as a C terminal fusion to thioredoxin using T4DNA
ligase (TA cloning kit, Invitrogen, Carlsbad, CA). The resulting
plasmid was sequenced in order to confirm that the insert was in
the correct orientation and that the sequence matched the native
gene sequence. The plasmid was transformed into the AD494
bacterial host strain (Novagen, Madison, WI) and plated on LB
plates containing ampicillin and kanamycin overnight at 37°C.
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Figure 1 (A) Reverse transcription-polymerase chain reaction analysis of
non-angiogenic (NA) and an angiogenic (A) vein disk for sst 2 transcripts.
MW, molecular weight markers. (B) Reverse transcription-polymerase chain
reaction analysis of non-angiogenic (NA) and an angiogenic (A) vein disk for
GAPDH transcripts. MW, molecular weight markers. The source of the
mRNAs for this reaction was the same as used in A 
Table 1 Primers and probes used in this study 
Primers 
sst 2 antisense CAG TTC AGA TAC TGG TTT GGA G 
sst 2 sense AGC CAT GGA CAT GGC GGA TGA G 
GAPDH antisense GTC ATG AGC CCT TTC ACG ATG C 
GAPDH sense GAA TCT ACT GGC GTC TTC AC C 
Probes 
sst 2 GAG GTC AAA TGG AAT GGA TAG CCA TGT GTG
GCT TCC ATT GAG 
GAPDH GTG ATG GGT GTC AAC CAC GAC 
*Primers and probes were synthesized by the Core Laboratories of the LSU
Health Sciences Center. 268 JC Watson et al
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Colonies were picked and cultured in 20 ml LB medium
(containing 100 mg ml–1 ampicillin and 30 mg ml–1 kanamycin)
overnight at 37°C in a shaking incubator. Bacterial cultures were
diluted 1:50 with fresh medium and cultured 3 to 4 hours until the
O.D. at 600 nm was greater than 0.6. Isopropylthio-b-D-galactosi-
dase (IPTG) was added to a final concentration of 1 mM to induce
protein expression. After 2 hours bacteria were collected by
centrifugation at 8000 g for 10 minutes. The pellets were resus-
pended in start buffer (1 ´ PBS and 10 Mm imidazole, pH 7.4) and
sonicated using a Polytron® at setting 7 with 5 second bursts for 1
minute to release the sst 2 peptide. Supernatants were collected
and pellets sonicated again. The sst 2-containing supernatant was
filtered through a 0.45 mm filter (Nalgene, Rochester, NY) and the
protein concentration was determined. The peptide was purified
using the Pharmacia His Trap® column system (Amersham
Pharmacia Biotech, Piscataway, NJ), dialysed against a 0.9% NaCl
solution overnight at 4°C, and concentrated using a Centriplus®
concentrator (Amicon, Beverly, MA). 
3 kg male rabbits were immunized with 500 mg sst 2 peptide in
0.5 ml 0.9% NaCl emulsified with an equal volume of Freund’s
complete adjuvant. The emulsion was injected both intramuscu-
larly and intradermally. Four booster injections (100 mg peptide)
were given at 3-week intervals. Serum was collected before each
booster injection and 3 weeks after the final injection and stored at
–20°C. This antibody has been previously characterized by Balster
et al (2001) and Albers et al (2000). 
Immunohistochemical staining 
Placental vein disks were cultured in 48-well plate membrane-
bottomed inserts. Disks which visually exhibited an angiogenic
response were fixed in 10% neutral-buffered formalin and embedded
in paraffin using standard tissue processing techniques. Serial 4 mm
slices were obtained and every tenth slide stained with haematoxylin
and eosin until the portion of the block containing the vessel disk was
reached. Factor VIII staining was performed to confirm that vascular
endothelial cells were present in the outgrowths. 
Paraffin sections of the vessel/fibrin clot were deparaffinized
and incubated in 3% H2O2 for 15 minutes at room temperature,
washed in distilled water (dH2O) and placed and preheated in
Antigen Retrieval® (Biogenix, San Ramon, CA) solution. Slides
were microwaved for 10 minutes on medium power and left in
sealed container for 15 minutes, followed by washing in dH2O 3
times and then in OptiMax Wash Buffer® (Biogenix). Slides were
incubated in PeroxiDaze 1® (Biocare Medical, Walnut Creek, CA)
for 15 minutes at room temperature, again washed in OptiMax
buffer, and incubated in Power Block® (Biogenix, San Ramon,
CA) for 10 minutes. A 1:1000 dilution of sst 2 antiserum (or a
1:1000 dilution of preimmune serum) in diluent buffer (Biomedia,
Foster City, OH) was added to separate slides and incubated at 4°C
overnight. Slides were washed in OptiMax Wash Buffer® for 20
minutes at room temperature. Secondary antibody (Biogenix
multilink super sensitive biotinylated antibody) was added to the
sections which were incubated for 20 minutes at room tempera-
ture. Slides were rinsed in OptiMax Wash Buffer® for a minimum
of 20 minutes, followed by incubation in conjugated streptavidin
(Biogenix) for 20 minutes. Slides were rinsed in OptiMax Wash
Buffer® for 20 minutes. AEC (3-amino-9-ethyl-carbazole) chro-
mogen was applied for 10 to 20 minutes, followed by rinsing in
OptiMax Wash Buffer® and dH2O. Slides were lightly counter-
stained with haematoxylin for 10 seconds followed by 3 seconds in
ammonia water, rinsed in dH2O, coverslipped with Crystal mount,
placed in a 60°C oven for 15 minutes and the cover slip sealed
with Permount (Biogenix, San Ramon, CA). 
RESULTS 
Gene expression in quiescent, proliferating and non-
proliferating placental vein cultures 
We analysed sst 2 receptor mRNA expression in non-proliferating
vein and proliferating placental vein endothelial cells obtained
from 6 placentas. In each of the placental samples, we found that
sst 2 gene expression was absent in non-proliferating endothelial
cells but was present in the proliferating endothelium (Figure 1A).
GAPDH mRNA was expressed in all samples (Figure 1B). Sst 2
gene expression was confirmed by Southern hybridization analysis
of the amplified gene products derived from proliferating placental
vein endothelial cells. Hybridization of the amplified gene product
with a sst 2 probe revealed a single product of the expected molec-
ular weight (Figure 2). 
Localization of radiolabelled somatostatin analogues in
angiogenic vessels in vivo 
Scans and radiographs were performed in register so that we could
compare relative radioligand uptake in the liver (normal route of
excretion) (Figure 3A) and in the tumour (Figure 3B). These scans
revealed significant radioligand uptake in the SKNSH tumour
even though the tumour cells do not express somatostatin recep-
tors. Alternatively, normal (non-proliferating) blood vessels in
non-tumour-bearing sites did not accumulate the radioligand,
implying that binding of the radioligand in the tumour was due to
sst 2 receptor expression on the angiogenic blood vessels
supplying the tumour. 
Immunohistochemical staining of vein disks 
To confirm the endothelial nature of the sprouts from the vein
disks, factor VIII, staining was performed (Figure 4). Immuno-
histochemical staining for sst 2 receptors revealed the presence 
of the receptor protein on cells forming the vascular sprouts
(Figure 5). The vein disk did not stain for sst 2 receptors except at
the periphery of the disk, the origin of the neovascular sprouts.
This staining pattern was not seen in the non-angiogenic disks incu-
bated in the anti-sst 2 antiserum (not shown). Neither the angiogenic
nor the non-angiogenic vein disks exhibited staining following incu-
bation in the nonimmune serum (Figure 6). Previous work with this
AN A
Figure 2 Southern hybridization of the RT-PCR product shown in Figure 1
with an sst 2 probe demonstrates a single product of the appropriate
molecular weight in the mRNA from the angiogenic (A), but not in the mRNA
from the non-angiogenic (NA) vein disk sst 2 expression 269
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antibody demonstrated sst 2 staining on the endothelial cells of
peritumoral vessels in a mouse tumour xenograft model.
Absorption of the sst 2 antibody with sst 2 antigen ablated the
immunohistochemical staining of the peritumoral vessels (Albers
et al, 2000). 
DISCUSSION 
We have previously demonstrated in both the chicken chorioallan-
toic membrane (CAM) assays and the rabbit bFGF-induced
corneal micropocket angiogenesis models that octreotide acetate
will inhibit angiogenesis (Woltering et al, 1991; Barrie et al, 1993;
Patel et al, 1994; Conway et al, 1996). This inhibition is propor-
tional to a somatostatin analogue’s ability to inhibit growth
hormone which in turn is proportional to the analogue’s binding
affinity for sst 2 (Woltering et al, 1997). Inhibition of angiogenesis
in the CAM model is G-protein-, adenylate cyclase-, and calcium-
dependent similar to somatostatin inhibition of peptide release
from neuroendocrine cells (Patel et al, 1994). Based on these
observations, it appears that similar receptors and post-receptor
signal transduction pathways are responsible for somatostatin’s
ability to inhibit peptide release, tumour growth, and angiogenesis
(Bhatena et al, 1981; Thompson et al, 1986; Woltering et al, 1986;
Wynick and Bloom, 1991). 
The widespread use of radiolabelled somatostatin analogues in
patients with neuroendocrine tumours has demonstrated that these
sst 2-containing tumours avidly bind radiolabelled sst 2-preferring
somatostatin analogues such as tyr3-octreotide, lanreotide, and
pentetreotide (Schirmer et al, 1993; Woltering et al, 1994;
Martinez et al, 1995; Woltering et al, 1995; McCarthy et al, 1998;
Cuntz et al, 1999; Espenan et al, 1999). Inevitably, as larger
numbers of tumour-bearing patients have been scanned with these
radiolabelled analogues, tissues and organs subjected to non-
tumour disease processes have been shown to bind these radioli-
gands. In a study by van Hagen et al, 111In-pentetreotide localized
to joints actively involved in rheumatoid disease (van Hagen et al,
1994). This is in contrast to a lack of binding seen in osteoarthritic
joints. One of the prominent features of rheumatoid arthritis is the
development of a vascular pannus in the active rheumatoid joint, a
feature absent in normal joints, quiescent rheumatoid joints, and
osteoarthritis joints. Vascularization of the rheumatoid joint is felt
to contribute to joint destruction seen in rheumatoid arthritis.
Localization of pentetreotide to the active rheumatoid, vascular-
ized joint is consistent with our observation that neovessel forma-
tion is associated with expression of sst 2. 
Several authors have demonstrated that radiolabelled sst 2-
preferring somatostatin analogues will bind to a variety of tumour
cell types, including breast cancer, endocrine tumours, renal cell
carcinomas, melanomas, neuroblastomas, medulloblastomas,
high-grade gliomas, high-grade lymphomas, meningiomas,
Merkel cell tumours, and small cell carcinomas of the lung
(Woltering et al, 1995). More recently, others have demonstrated
Figure 3 (A) Scintographs and radiographs were performed in register to compare relative radioligand uptake in the liver (normal route of excretion). The
SKNSH tumour (sst 2-negative) shows intense uptake of a radiolabelled sst 2-preferring somatostatin analogue. (B) Scintographs and radiographs were
performed in register to compare relative radioligand uptake in the tumour. The SKNSH tumour (sst 2-negative) shows intense uptake of a radiolabelled
sst 2-preferring somatostatin analogue 270 JC Watson et al
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that prostate cancers will selectively bind radiolabelled somato-
statin analogues, however, the level of binding is less than that
seen in endocrine neoplasms (Nilsson et al, 1995; Kalkner et al,
1998). Other tumours have been imaged with radiolabelled
analogues and in many instances subsequent evaluation of these
tumours by autoradiography shows little or no uptake or binding of
the radiolabelled analogue by tumour cells. We believe that radio-
labelled analogue binding to tumour-associated angiogenic blood
vessels may explain tumour imaging in sst 2-negative tumours. In
almost all tumour types, high-grade lesions have more intense
ligand binding than low-grade lesions, an observation consistent
with a poorly differentiated tumour developing a more intense
angiogenic response. 
These findings may have considerable clinical relevance. An
angiogenic response is required for a tumour to grow beyond a
diameter of 2 mm. The expression of sst 2 in angiogenic vessels
implies that tumours greater than 2 mm in diameter might bind sst
2-preferring radiolabelled somatostatin analogues either to their
Figure 4 Factor VIII staining of endothelial cell sprouts from a vein disk (40X) 
Figure 5 Immunohistochemical stain for sst 2 receptors on endothelial cell
sprouts (20X) 
Figure 6 Absence of staining following incubation of a section of an
angiogenic disk in nonimmune serum (40X) tumour cells, their angiogenic neovessels, or both. This observa-
tion provides encouragement for the development of specific sst 2
targeted therapy in tumours with homogeneous or heterogeneous
receptor distribution. 
Other investigators have noted that tumour cell expression of sst
2 is heterogeneous and that radiolabelled somatostatin analogue
therapy is best accomplished by the use of high-energy radioiso-
topes (Bootsma et al, 1993). While the heterogeneous expression
of sst 2 on tumour cells is ubiquitous, it appears that all prolifera-
tive neovessels homogeneously express this receptor. This differ-
ence in receptor expression may permit the use of low energy
radioisotopes for therapy (McCarthy et al, 1998; Espenan et al,
1999). Sst 2-targeted applications may include intraoperative
gamma localization of occult primary tumours, and intraoperative
gamma detection of microscopically positive primary tumour
resection margins (Schirmer et al, 1993; Woltering et al, 1994;
Martinez et al, 1995; Cuntz et al, 1999). This sensitive technique
may also allow the detection of small deposits of tumour in lymph
nodes or in areas outside the normal field of resection (Woltering
et al, 1994). Other applications of sst 2-targeted techniques include
external scintigraphic imaging and in situ radiotherapy. Recent
reports on the use of low energy Auger electron emitters, such as
111In pentetreotide for therapy of sst 2-expressing tumours are
encouraging (McCarthy et al, 1998; Espenan et al, 1999). Others
have used high-energy radiolabelled somatostatin analogues for
therapy, hoping that higher energy radioisotopes will induce cell
death in adjacent receptor-negative cells (Zamora et al, 1997;
Espenan et al, 1999). Somatostatin analogues can also be conju-
gated to chemotherapeutic agents or toxins and may provide
highly targeted tumoricidal or angiocidal therapy (Plownoski et al,
2000). 
The results of this study reveal that sst 2 expression occurs when
vascular endothelial cells begin to grow. The finding paves the
way for the development of a highly specific target for anti-angio-
genic therapy using sst 2-preferring somatostatin analogues. 
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